Welcome to our dedicated page for TruBridge SEC filings (Ticker: TBRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TruBridge, Inc. (NASDAQ: TBRG) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, drawn in real time from the EDGAR system and supported by AI-powered analysis. TruBridge is a healthcare technology and solutions company focused on rural and community hospitals and providers, and its filings offer detailed insight into how it reports financial performance, manages risk, and governs its operations.
Key documents for TruBridge include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company presents audited and interim financial statements, segment information for its Financial Health and Patient Care business units, and discussions of risk factors and internal control over financial reporting. For example, TruBridge has disclosed material weaknesses related to revenue processes and customer contract changes in prior years, and it has reported on changes to its independent registered public accounting firm, including the dismissal of Grant Thornton LLP and engagement of KPMG LLP.
Current reports on Form 8-K capture material events such as quarterly earnings releases, leadership changes, board refreshment actions, cooperation agreements with major shareholders, and financing developments like the 2025 Amended and Restated Credit Agreement with its lending partners. These filings help investors understand how TruBridge is addressing governance, capital structure, and strategic priorities in the context of rural and community healthcare.
On this page, users can review TruBridge’s Forms 10-K and 10-Q, 8-Ks describing significant corporate events, and other exhibits referenced in those reports. AI-generated summaries highlight the main points of each filing, explain complex accounting or control matters in plain language, and surface items related to revenue cycle management, EHR and patient engagement operations, internal control conclusions, and auditor changes. Filings related to executive and director arrangements, such as severance agreements and board appointments, are also accessible, along with any associated exhibits.
By using these tools, readers can quickly understand what TruBridge reports to regulators about its financial health, operational segments, governance, and risk profile, without having to parse every line of the underlying documents themselves.
TruBridge, Inc. reported fourth quarter and full year 2025 results and outlined a broad strategic review. For 2025, revenue was $346.8 million versus $342.2 million in 2024, while net income swung to a $4.4 million profit from a $20.9 million loss.
Adjusted EBITDA rose to $68.7 million with a 19.8% margin, up from 16.3%, reflecting cost controls and offshoring initiatives. Cash grew to $24.9 million with total assets of $402.5 million and stockholders’ equity of $178.0 million. Total 2025 bookings were $82.9 million, with Annual Contract Value bookings of $70.9 million.
The company is reviewing alternatives to maximize shareholder value, including potential asset sales, combinations, repurchases, or organic investments, while cautioning that no transaction is assured. Management also identified and revised immaterial errors in prior-period financials, mainly around revenue timing and capitalized software costs, after concluding they were not material to 2023–2025 results.
TruBridge, Inc. Controller MacIntyre Vita reported a routine tax-related share disposition. On the vesting of restricted stock, 187 shares of common stock were withheld at a price of $14.07 per share to cover tax obligations. After this non-market transaction, Vita directly holds 1,778 TruBridge common shares.
TruBridge, Inc. executive Wilson Merideth, who serves as Financial Health GM, reported a routine tax-related share disposition. On March 13, 2026, 604 shares of common stock were withheld at $17.31 per share to cover taxes upon vesting of restricted stock. After this withholding, Merideth directly holds 6,836 shares of TruBridge common stock. This was not an open-market sale but an automatic tax-withholding event tied to equity compensation.
TruBridge, Inc. General Counsel Kevin Plessner reported routine tax-related share withholdings tied to restricted stock vesting. On March 13, 2026, 340 shares of common stock were withheld at $17.31 per share, and on March 16, 2026, 825 shares were withheld at $17.59 per share.
Both transactions are coded as tax-withholding dispositions rather than open-market sales. After these events, Plessner directly owns 12,012 shares of TruBridge common stock. The activity reflects payment of tax obligations on equity compensation rather than a change in investment stance.
TruBridge, Inc. Controller MacIntyre Vita reported a small insider transaction involving company common stock. On March 13, 2026, 125 shares were withheld at $17.31 per share to cover tax obligations tied to vesting of restricted stock, rather than an open-market sale. After this tax-withholding event, Vita directly owned 1,965 shares of TruBridge common stock.
TruBridge, Inc. General Manager Patient Care David Harse reported routine tax-withholding transactions related to restricted stock vesting. He had 571 shares of common stock withheld on March 13 at $17.31 per share and 1,098 shares withheld on March 16 at $17.59 per share to cover tax obligations, rather than selling shares in the open market. Following these dispositions, he directly holds 16,012 TruBridge common shares.
TruBridge, Inc. President and CEO Christopher L. Fowler reported routine share dispositions related to tax withholding on vested restricted stock. On March 16, 5,909 common shares were withheld at $17.59 per share, and on March 13, 2,213 shares were withheld at $17.31 per share to cover tax liabilities. After these transactions, Fowler directly held 117,089 common shares, and a further 16 shares were held indirectly by his spouse.
TruBridge, Inc. director David A. Dye reported routine tax-related share withholding tied to vesting of restricted stock. On March 13 and 16, 2026, a total of 4,078 shares of common stock were withheld at prices of $17.31 and $17.59 per share to cover tax obligations, rather than through open-market sales. After these transactions, Dye directly holds 83,635 shares of TruBridge common stock and indirectly holds 46,800 shares through a trust for his benefit and that of his children.
TruBridge, Inc. Chief Financial Officer Vinay Bassi reported routine tax-related share withholdings tied to vesting of restricted stock. On March 13, 2026, 1,758 shares of common stock were withheld at $17.31 per share, and on March 16, 2026, 3,965 shares were withheld at $17.59 per share.
These Form 4 transactions, coded as tax-withholding dispositions, were not open-market sales. After these events, Bassi directly held 37,801 TruBridge common shares, reflecting continued equity ownership following the RSU vesting-related withholdings.